Primary and Metastasized Bone Cancer

Precision Treatment Options for Primary and Metastasized Bone Cancers


Envita Medical Centers’ uniquely integrative and personalized approach to late-stage bone cancer utilizes next-level precision care including extensive genomic targeting, advanced immunotherapy, modulation of tumor microenvironment and specialized precision non-invasive surgery directed at the periosteum of the bone tumor and other satellite regions where the tumors reside. This all-encompassing approach helps our patients improve their overall responses to treatment.

Envita Medical Centers doesn't make any guarantee of outcomes. Results are not typical and will vary from person to person and should not be expected.

EnvitaIR™: A Non-Invasive Surgical Option for Bone Cancer Patients

Interventional Radiology (IR) is one of the many treatment options available for patients seeking bone cancer care. IR utilizes medical imaging and minimally invasive surgical procedures for oncological treatment of difficult to reach cancer types like cancers of the bone. With over 20 years of developing precision medicine and expanding non-invasive surgical options for late-stage and complex cancer patients, Envita Medical Centers has created EnvitaIR™, Envita’s Interventional Radiology and Immunotherapy Center.

EnvitaIR™ takes interventional radiology to the next level by incorporating patient-specific treatment algorithms based on exhaustive laboratory testing which targets proprietary customized immunotherapy and immunotherapy adjunctive agents best suited for the patient’s state of disease. Precision drug delivery via micro catheters allows for targeted deployment of conventional and custom compounded, patient-specific medication for localized and systemic effect throughout the patient’s body.

EnvitaIR™ takes full advantage of the latest advancements in precision interventional oncology using chemotherapy, radiation, and ablation therapy for direct tumor kill. Even further, EnvitaIR™ harnesses minimally invasive procedures to deliver genetically targeted immunotherapies, customized for each patient’s form of cancer, to regulate immunoreactive blockades that compromise the immune system.

Advantages of Envita Interventional Radiology

Minimally Invasive

EnvitaIR's™ procedures are performed without the need for large surgical incisions. Treatment is performed using small catheters the size of a human hair that are fed through the patient's veins to the area of interest allowing for precision administration with significantly faster recovery.

No General Anesthesia

Because EnvitaIR's™ treatments are minimally invasive, there is no need for general anesthesia reducing the health risks that can result from being put into a medically induced coma to perform a procedure.

Direct Tumor Targeting

EnvitaIR's™ has developed genetically targeted interventional radiology procedures that deliver patient-specific genomic agents directly to the tumor.

Immune System Activation

Tumor targeted genomic agent delivery causes a systemic immune system response that activates the immune system to seek out other metastatic cancer sites in the body.

Faster Recovery Times

Generally, the recovery time from a procedure will be much faster than traditional surgery methods due to its minimally invasive administration.

No Hospital Stays

EnvitaIR's™ procedures are performed in an outpatient setting by dedicated and highly trained medical professionals where an overnight hospital stay is not necessary.

Precision Results

There are many benefits to EnvitaIR’s™procedures but the truly unique factor is the precision custom genomic and immunotherapy options that are directly administered at the tumor site. This technology takes interventional oncology to the next level.

The key to Envita’s world-class, revolutionary care is tumor-specific, precision genomic analysis of real-time mutational rates and immune targets, combined with Envita’s proprietary treatment algorithms developed over our extensive years of experience working with late-stage and complex cancers. Envita’s highly experienced physicians use this critical information to formulate a customized treatment plan based on you, the patient, and your unique bone cancer expression.

Envita Medical Centers is at the forefront of medical technology, combining leading-edge precision cancer treatments with the latest innovations in non-invasive surgery, efficacious traditional medicine, and custom compounded natural, IV-based agents. For twenty years, Envita has helped thousands of late-stage and resistant-to-care cancer patients find amazing results through personalized protocols that are genetically optimized to treat each patient’s unique cancer, including primary sarcomas and metastatic bone tumors.

Let Envita Medical Centers be your Center of Excellence in the practice of precision integrative medicine for late-stage and refractory-to-care bone cancer. Through our two decades of clinical experience, Envita recognizes bone cancer patients need a precision-based approach utilizing advanced personalized treatment options that have been genetically targeted towards the patient’s specific actionable targets that are driving metastatic cancers.

The ability to provide this level of detailed analysis is why Envita stands out among other big-name facilities. Envita Medical Centers designs personalized protocols for late-stage cancer patients that have failed previously recommended treatments, going above-and-beyond the standardized approach to care.

Advanced Genetic Testing

Accurately targeting bone cancer is critically important. Late-stage metastasized cancers like cancers of the bone pose significant challenges to standard-of-care treatment regimens because often these cancers were not responsive to first and second-round treatment options, causing the cancer to grow uncontrollably. Moreover, the wrong chemotherapy selection can accelerate mutational rates and worsen a patient’s condition.

Standard of care’s one-size-fits-all, blanket treatments have little flexibility within their protocols to deal with these rapidly changing expressions of cancer. This approach to cancer treatment is best described as trying to hit a moving target by only focusing on where the target is at, as opposed to where it is going.

To understand the cancers trajectory and how to properly target it, next-generation genetic testing becomes the essential first step towards targeted treatment. With twenty years of clinical experience treating metastatic cancers, Envita physicians have found that having accurate real-time data is critical to discovering actionable targets for precision care. Using precision analysis of advanced genetic data and the patient’s complete medical history, Envita builds completely customized genetically targeted protocols for each patients’ unique needs, providing a higher degree of personalized medicine.

Envita's advanced form of genetic testing gives our doctors access to real-time CTC data which is used to detail the patient's medical blueprint and their metastasized bone cancer's genetic biomarkers.

Envita’s precision analysis of the most up-to-date genomics is used to identify targets for care which include the cancer’s microenvironment, microsatellite instability, epigenetic influences on mutation, and suppressed immuno-reactivity. It is only when all these areas have been properly tested for and addressed can a patient begin to experience true personalized care.

Standard cancer care does not adequately address the continuously updating genetic information on cancer biomarkers and chemo susceptibility, which are important for staying ahead of the constantly changing cancer environment. Advanced immunotherapy and immunotherapy adjunctive agents are essential in activating the body’s immune system to reestablish its ability to fight cancerous lesions.

By utilizing precision-based genetic testing to determine patient-specific oncogenes and tumor suppressor genes correlated with a patient’s unique cancer presentation, Envita can put the pieces together and create a personalized medical blueprint designed to attack the cancer from multiple angles with dynamic protocols that update with the cancer’s mutations.

Envita Medical Centers doesn't make any guarantee of outcomes. Results are not typical and will vary from person to person and should not be expected.

This real-time information guides advancements in Envita’s personalized epigenomic and miRNA protocols designed to downregulate oncogenes and upregulate tumor suppressor genes. Oncogenes are responsible for perpetuating the growth and spread of cancer, while tumor suppressor genes are genes that can reactivate the body's immune response against cancerous cells.

A healthy immune system can precisely and efficiently kill thousands of cancerous cells daily. Envita’s unique treatment options work to correct and take advantage of these processes by identifying and modulating patient-specific oncogenes and tumor suppressor genes to turn off cancer signaling and turn on the immune system’s ability to identify and attack the cancerous cells.

Finally, treating the causes of cancer can be just as important as attacking cancerous cells themselves. Envita utilizes extensive genomic testing to identify toxins, infections, and other harmful agents that may be playing a role in not only proliferating cancerous cell growth and formation but also limiting treatment efficacy and suppressing the patient’s immune system.

A comprehensive treatment protocol that is personalized to match each patients’ individual needs and their cancers unique weaknesses is key in creating Envita’s customized treatment plans. The medical blueprint Envita develops based on state-of-the-art testing is a cornerstone for providing this high level of precision treatment.

Treating Metastasized Cancers

Envita’s advanced genetic analysis provides crucial information about a patient’s cancer, its mutations, and the microenvironment surrounding the tumor. Cancer’s microenvironment contains many crucial elements that need to be addressed in order to successfully eradicate the tumor and halt metastasis. These elements include Circulating Tumor Cells (CTCs), Vascular Endothelial Growth Factors (VEGF), and Microsatellite Instability (MSI).

Evidence suggests that Circulating Tumor Cells or CTCs carry the most recently mutated form of the cancer’s genetic markers [1]. Envita employs proprietary technology designed to corral these CTC’s and provide real-time genetic information which is used to detail the patient’s medical blueprint and their metastasized cancer’s genetic biomarkers.

Envita's individualized cancer protocols combine minimally invasive, genetically targeted, low-dose chemotherapy options with custom compounded immunotherapy and immunotherapy adjunctive agents.

A patient’s medical blueprint is used in combination with Envita’s customized treatment algorithms to precisely track and treat mutational rates, immunotherapy targets, and genomic markers. Using this blueprint and twenty years of clinical experience treating metastatic cancers, Envita doctors create a detailed and customized comprehensive treatment strategy that focuses on addressing key factors in the development and circulation of cancer cells.

Vascular Endothelial Growth Factors, or VEGFs, promote the formation of new and irregular blood vessels [2]. These irregular vessels can help tumors grow, and cancerous cells spread [2]. Envita’s doctors utilize personalized treatment protocols that combine customized integrative medicines with antiangiogenic smart drug technology that can silence cancerous blood vessel growth.

By tracking and treating the unique microenvironment around the cancer, Envita’s personalized treatment protocols are designed to potentially decelerate and prevent further metastasis by slowing the spread of CTCs.

Microsatellite Instabilities (MSI) are theorized to be the outcome of mutations that occur during DNA replication [3]. MSI can facilitate the continued mutation of the cancerous cells in the bone and throughout the body [4], resulting in constantly changing treatment targets that can complicate and derail treatments.

Envita utilizes next generation testing to accurately measure mutational rates and develop precision treatment algorithms to deploy correlated therapies. Envita has developed treatments to address microsatellite instability to help keep our patients one step ahead of their disease and improve their chances for a positive outcome.

Precision interventional oncology solutions provide treatment options that not only target the cancerous regions directly, but also incorporate epigenomic and miRNA immunotherapy designed to address the microenvironment supporting the growth and mutation of the cancer. These treatments offer options far beyond what may be available from conventional radiology and invasive surgery for bone cancers.

CIPI™, one of Envita’s most exciting new interventional radiology treatment options, utilizes the precision techniques of interventional non-invasive surgery with micro-dosed chemotherapy delivered directly to the tumor, offering a unique approach to treatment of complex cancers.

CIPI™: Chemo Immuno Precision Injections

For many late-stage and progressive cancer patients, continuing to perform untargeted chemotherapy regimens can lead to further cancerous mutations. This is especially common for patients with tumors that are difficult to penetrate and reach through traditional chemotherapy administration options, like bone cancers.

Envita Medical Centers is one of the world’s leading integrative medical centers focused on innovating and improving technologies and therapies to better serve the needs of cancer patients. For patients suffering from bone cancers and other hard to treat tumors, Envita is excited to offer a customized precision approach to interventional oncology called Chemo Immuno Precision Injections (CIPI™).

The CIPI™ procedures ingenuity lies in its personalized interventional radiology approach that precisely delivers genetically targeted medications directly into the cancerous tumors, while leaving the patient with potentially reduced side-effects from the use of minimally invasive delivery techniques.

A graphical image depicting COVID-19's mortality rate by age
CIPI™ is a minimally invasive procedure that utilizes a catheter no thicker than a human hair which is fed from an appropriate vessel through the body and into the cancerous tumor.

By utilizing the patient’s advanced medical blueprint and delivering truly personalized care, Envita provides a level of precision medicine that goes beyond what other treatment centers can offer. The proprietary therapies derived combines comprehensive and highly detailed testing with genetically targeted medications and natural adjuvant agents, allowing for customized treatments that focus on the patient’s specific needs.

Envita helped thousands of late-stage and resistant-to-care cancer patients find amazing results through personalized protocols that are genetically optimized to treat each patient's unique cancer, including primary sarcomas or metastatic bone tumors.

Immuno-Ablation

Immuno-Ablation is another innovative and leading-edge therapy that allows Envita’s physicians to deliver precision ablation to painful spinal and bone tumors after establishing immunoreactivities to the cancer. The treatment aims to stimulate immunity via periosteum activation at the bone cancer site.

The bone is a hematopoietic organ that is involved in the origination of red blood cell and immune cells. These mutated cells add complexity to mutation along with immune system resistance to treatment.

Immuno-ablation focuses on reestablishing the body’s immunity to the cancer and then ablating the tumor using a minimally invasive approach that allows for faster recovery. This alternative to highly invasive surgery can also destroy painful metastatic tumors in a simple outpatient procedure that has a minimal potential for side-effects.

Envita’ s interventional radiology division provides the ability to directly target bone tumors without the need to put the patient under general anesthesia to perform extremely invasive surgical procedures, which have their own risks beyond the tumor itself, greatly improving the quality of life and recovery for the patient.

Conclusion

Envita Medical Centers has spent twenty years treating the most aggressive and resistant late-stage cancers. In that time, we have helped thousands of cancer patients from all around the world, including many stage four cancers patients with metastatic bone cancer, find real success against their condition.

We know that most cases of bone cancer result from late-stage cancers that have spread throughout the body, and this can result in resistant cancers that can be difficult to treat. The standard protocols for treating these late-stages of cancer and metastasized bone cancers may involve invasive surgeries and one-size-fits-all chemotherapies or radiation treatments.

These methods can cause extensive damage when not properly targeted, therefore Envita strives to offer the most advanced personalized therapies and treatment protocols from around the world to help patients that are looking for alternative solutions.

By utilizing in-depth genetic testing combined with one-of-a-kind targeted treatments, Envita stacks the odds in the patients favor to potentially achieve positive outcomes. Many patients finish treatment at Envita and wish they would have found us sooner; they leave grateful to have experienced the incredible healing that happens at Envita Medical Center.

Our team of 160 dedicated staff from physicians, chemists, pharmacists, and researchers working with the most difficult and late-stage cancers recognize that the sooner detailed planning and precision is implemented for your care, the better your chances for success in our clinical experience.

To learn more about how we may be able to help you with your specific situation contact us; we have expert team that works hand and hand with our doctors to help review your case and we are here to help.

If you or a loved one is suffering from metastatic bone cancer, please do not hesitate to reach out to Envita’s Patient Care Team at 866-830-4576 and let us help you discover the power of targeted and personalized care.


References

[1] Van der Toom, E.E., et al., Technical challenges in the isolation and analysis of circulating tumor cells. Oncotarget, 2016. 7(38): p. 62754-62766.

[2] Kowanetz, M. and N. Ferrara, Vascular Endothelial Growth Factor Signaling Pathways: Therapeutic Perspective. Clinical Cancer Research, 2006. 12(17): p. 5018.

[3] Boland, C.R. and A. Goel, Microsatellite Instability in Colorectal Cancer. Gastroenterology, 2010. 138(6): p. 2073-2087.e3.

[4] Park, S.W., et al., Somatic frameshift mutations of bone morphogenic protein receptor 2 gene in gastric and colorectal cancers with microsatellite instability. APMIS, 2010. 118(11): p. 824-829.

To better understand our unique approach to cancer treatment: